Abstract: A separator includes a porous substrate and a porous coating disposed on at least one surface of the porous substrate, where the porous coating includes a polymer and a thickness covariance value of the separator is 0.01 to 0.02. The separator provided has good thickness consistency, which is conducive to improving the packaging performance of the electrochemical device, and the resulting electronic device has a longer service life and good usage performance.

Abstract: A separator includes a porous substrate and a porous coating disposed on at least one surface of the porous substrate, the porous coating includes a polymer, and the polymer includes polymer particles. In a 130 ?m×100 ?m region on a surface of the porous coating, the number of the polymer particles with a maximum diameter in a range of 5 ?m to 14 ?m is 100 to 180. The separator has large-particle size polymer that can increase the interface gap at the corners of the electrochemical device. Thus, for the electrochemical device, the electrolyte at the corner interfaces can achieve good infiltration during the charge-discharge cycling process, effectively alleviating the corner purple/black spot problem of the electrochemical device.

Abstract: The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: The present invention is drawn to cyclic RGD peptides linked via a disulfide bond, where the terminal cysteines are preferably in the D configuration. These peptides target ?v?3 integrin on tumor cells and neovasculatures and function as targeting agents for tumor diagnostic imaging and therapy. Compared with the commonly used RGD ligands, compounds of the present invention have improved targeting efficacy and lower nonspecific binding to normal organs. Moreover, the compounds of the present invention can be functionalized to conjugate imaging payload without decreasing binding strength.

Abstract: The present invention is drawn to cyclic RGD peptides linked via a disulfide bond, where the terminal cysteines are preferably in the D configuration. These peptides target ?v?3 integrin on tumor cells and neovasculatures and function as targeting agents for tumor diagnostic imaging and therapy. Compared with the commonly used RGD ligands, compounds of the present invention have improved targeting efficacy and lower nonspecific binding to normal organs. Moreover, the compounds of the present invention can be functionalized to conjugate imaging payload without decreasing binding strength.

Abstract: The present invention is drawn to cyclic RGD peptides linked via a disulfide bond, where the terminal cysteines are preferably in the D configuration. These peptides target ?v?3 integrin on tumor cells and neovasculatures and function as targeting agents for tumor diagnostic imaging and therapy. Compared with the commonly used RGD ligands, compounds of the present invention have improved targeting efficacy and lower nonspecific binding to normal organs. Moreover, the compounds of the present invention can be functionalized to conjugate imaging payload without decreasing binding strength.